KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Notes Payables (2024 - 2025)

Historic Notes Payables for Esperion Therapeutics (ESPR) over the last 2 years, with Q3 2025 value amounting to $54.9 million.

  • Esperion Therapeutics' Notes Payables changed N/A to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.9 million, marking a year-over-year change of. This contributed to the annual value of $54.6 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Esperion Therapeutics reported Notes Payables of $54.9 million as of Q3 2025.
  • Esperion Therapeutics' Notes Payables' 5-year high stood at $54.9 million during Q3 2025, with a 5-year trough of $54.6 million in Q4 2024.